Chemical synthesis and biological properties of novel fluorescent antifolates in Pgp- and MRP-overexpressing tumour cell lines

Biochemical Pharmacology

Volumn 56, Issue 7, 1998, Pages 807-816

  Robson, Claire ^a   Wright, Karen A ^b   Twentyman, Peter R ^b   Lambert, Peter A ^c   Griffin, Roger J ^c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

Drug transport; Flow cytometry; Fluorescent probes; Lipophilic antifolates; MRP; Multidrug resistance

Indexed keywords

CYCLOSPORIN A; FLUORESCENT DYE; FOLIC ACID ANTAGONIST; GLYCOPROTEIN P; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL;

ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL LINE;

4-CHLORO-7-NITROBENZOFURAZAN; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; DANSYL COMPOUNDS; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENT DYES; FOLIC ACID ANTAGONISTS; GROWTH INHIBITORS; HUMANS; LUNG NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PYRIMIDINES; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETREXATE; TUMOR CELLS, CULTURED; UMBELLIFERONES;

EID: 0032190466     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00068-9     Document Type: Article

References (39)

1. Sigel C.W., Macklin A.W., Woolley J.L. Jr, Johnson N.W., Collier M.A., Blum M.R., Clendenin N.J., Everitt B.J.M., Grebe G., Mackars A., Foss R.G., Duch D.S., Bowers S.W., Nichol C.A. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. Natl Cancer Instit Monogr. 5:1987;27-35.
2. Lin J.T., Bertino J.R. Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Invest. 9:1991;159-172.
3. Berman EM and Werbel LM, The renewed potential for folate antagonists in contemporary cancer chemotherapy. J Med Chem 34: 479-448, 1991.
4. Schweitzer B.I., Dicker A.P., Bertino J.R. Dihydrofolate reductase as a therapeutic target. FASEB J. 4:1990;2441-2452.
5. Queener S.F. New drug developments for opportunistic infections in immunosuppressed patients Pneumocystis carinii . J Med Chem. 38:1995;4739-4759.
6. Voelker R. More choices in treating AIDS-related pneumonia. J Am Med Assoc. 271:1994;176-177.
7. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem. 62:1993;385-427.
8. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG, Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654.
9. Cole S.P., Sparks K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., Deeley R.G. Pharmacological characterisation of multidrug-resistant MRP-transfected human tumor cells. Cancer Res. 54:1994;5902-5910.
10. Loe D.W., Deeley R.G., Cole S.P. Biology of the multidrug resistance associated protein MRP. Eur J Cancer. 32A:1996;945-947.
11. Klohs W.D., Steinkampf R.W., Besserer J.A., Fry D.W. Cross resistance of pleiotropically drug resistant P388 leukemia cells to the lipophilic antifolates trimetrexate and BW 301U. Cancer Lett. 31:1986;253-260.
12. Assaraf Y.G., Molina A., Schimke R.T. Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug resistant phenotype. J Natl Cancer Inst. 81:1989;291-294.
13. Baccanari D.P., Tansik R.L. Multiple drug resistance and its relationship to brain penetration by lipophilic dihydrofolate reductase inhibitors. Proc Am Assoc Cancer Res. 31:1990;339.
14. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells of blood-brain barrier sites. Proc Nat Acad Sci USA. 86:1989;695-698.
15. Tsuji A., Tamai I. Blood-brain barrier function of P-glycoprotein. Adv Drug Delivery Rev. 25:1997;287-298.
16. Pardridge W.M., Golden P.L., Kang Y.S., Bickel Y. Brain microvascular and astrocyte localization of P-glycoprotein. J Neurochem. 68:1997;1278-1285.
17. Raderer M., Scheithauer W. Clinical trials of agents that reverse multi-drug resistance - A literature review. Cancer. 72:1993;3553-3563.
18. Griffin R.J., Meek M.A., Schwalbe C.H., Stevens M.F.G. Structural studies on bio-active compounds. Part 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant cell line. J Med Chem. 32:1989;2468-2474.
19. Robson C., Meek M.A., Grunwaldt J.-D., Lambert P.A., Queener S.F., Schmidt D., Griffin R.J. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii, and as antitumor agents . J Med Chem. 40:1997;3040-3048.
20. Robson C, Wright KA, Twentyman PR and Griffin RJ, Resistance to fluorescent antifolates in Pgp- and MRP-overexpressing tumour cell lines. Br J Cancer 73 (Suppl 16): 33, P28, 1996.
21. Griffin R.J., Schwalbe C.H., Stevens M.F.G., Wong K.P. Structural studies on bio-active compounds. Part 3. Re-examination of the hydrolysis of the antimalarial drug pyrimethamine and related derivatives and crystal structure of a hydrolysis product. J Chem Soc Perkin Trans. 1:1985;2267-2276.
22. Twentyman P.R., Fox N.E., Wright K.A., Bleehen N.M. Derivation and preliminary characterisation of adriamycin resistant cell lines of human lung cancer cell lines. Br J Cancer. 53:1986;529-537.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxic methods . J Immunol Methods. 65:1983;55-63.
24. Twentyman P.R., Luscombe M. A study of some of the variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 56:1987;279-285.
25. Watson J.V. Enzyme kinetic studies in all cell populations using fluorogenic substrates and flow cytometric techniques. Cytometry. 1:1980;143-151.
26. Denny B.J., Ringan N.S., Schwalbe C.H., Lambert P.A., Meek M.A., Griffin R.J., Stevens M.F.G. Structural studies on bioactive compounds. 20. Molecular modelling and crystallographic studies on methylbenzoprim, a potent inhibitor of dihydrofolate reductase. J Med Chem. 35:1992;2315-2320.
27. Brown C.S., Cunningham L.W. Reaction of reactive sulfhydryl groups of creatine kinase with dansyl chloride. Biochemistry. 9:1970;3878-3885.
28. Ghosh P.B., Whitehouse M.W. A new fluorigenic reagent for amino acids and other amines. Biochem J. 108:1968;155-156.
29. Kozikowski A.P., Kotoula M., Ma D., Boujrad N., Tückmantel W., Papadopoulos V. Synthesis and biology of a 7-nitro-2,1,3-benzoxadiazol-4-yl derivative of 2-phenylindole-3-acetamide A fluorescent probe for the peripheral-type benzodiazepine receptor . J Med Chem. 40:1997;2435-2439.
30. Bengueddour R., Matt M., Nicolas A., Donner M., Stoltz J.F. Liquid chromatography after pre-column derivatization with fluorescent reagents. Anal Lett. 26:1993;429-443.
31. Assaraf Y.G., Schimke R.T. Identification of methotrexate transport deficiency in mammalian cells using fluoresceinated methotrexate and flow cytometry. Proc Natl Acad Sci USA. 84:1987;7154-7158.
32. Urlaub G., McDowell J., Chasin L.A. Use of fluorescence-activated cell sorter to isolate mutant mammalian cells deficient in an internal protein, dihydrofolate reductase. Somatic Cell Mol Genet. 11:1985;71-77.
33. Assaraf Y.G., Molina A., Schimke R.T. A fluorescein-methotrexate-based flow cytometric bioassay for measurement of plasma methotrexate and trimetrexate levels. Anal Biochem. 178:1989;287-293.
34. DeGraaf D., Sharma R.C., Mechetner E.B., Schimke R.T., Roninson I.B. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci. 93:1996;1238-1242.
35. Heijn M., Hooijberg J.H., Scheffer G.L., Szabo G., Westerhoff H.V., Lankelma J. Anthracyclines modulate multidrug resistance protein (MRP) mediated organic ion transport. Biochim Biophys Acta. 1326:1997;12-22.
36. Cole S.P., Downes H.F., Slovak M.L. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br J Cancer. 59:1989;42-46.
37. Barrand M.A., Rhodes T., Center M.S., Twentyman P.R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer. 29A:1993;408-415.
38. Bertino J.R., Fischer G.A. Technique for the study of resistance to folic acid antagonists. Methods Med Res. 10:1964;297-299.
39. Jackson R.C., Hart L.I., Harrap K.R. Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrofolate reductases. Cancer Res. 36:1976;1991-1997.